ARALEN
LOE ApproachingNDAORALTABLET
Approved
Oct 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARALEN is a legacy oral tablet approved in 1949 by Sanofi for undisclosed indications. The specific mechanism of action and therapeutic uses are not provided in available data, but the product represents a historical small-molecule entity with nearly 75 years of clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling a defensive, cost-management focused team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ARALEN offers minimal linked job opportunities and represents a defensive, mature-stage career assignment. Professionals on this product should expect focus on margin protection, cost management, and generic transition planning rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on ARALEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.